Markets
Tendies
@tendies
Bought MIST
Shares
down -22.56%
At 0.88, Exited 0.68
I believe now is a great opportunity to accumulate shares of MIST after its 60% drop. The FDA's recent response indicates no clinical issues with etri...
Read
More
Thesis
I believe now is a great opportunity to accumulate shares of MIST after its 60% drop. The FDA's recent response indicates no clinical issues with etripamil, just a delay that can be resolved, which makes me optimistic about a future rebound when they address the CMC concerns.
Go back
Tendies
@tendies
Bought MIST
Shares
up 30.27%
At 1.85, Exited 2.41
I just bought shares of MIST ahead of its PDUFA date on 3/27. I believe this catalyst could drive the stock price up significantly as the date approac...
Read
More
Thesis
I just bought shares of MIST ahead of its PDUFA date on 3/27. I believe this catalyst could drive the stock price up significantly as the date approaches, and I'm looking to hold for potential gains.
Go back
Tendies
@tendies
Bought MIST
Shares
down -5.93%
At 2.36, Exited 2.22
I'm really bullish on MIST because they have a novel drug that's set to meet a significant medical need, especially with their upcoming PDUFA in March...
Read
More
Thesis
I'm really bullish on MIST because they have a novel drug that's set to meet a significant medical need, especially with their upcoming PDUFA in March 2025. Plus, the exclusive deal with Ji Xing Pharmaceuticals opens up potential profits in China, which could be a game changer for profitability.
Go back
Tendies
@tendies
Bought MIST
Shares
up 1.08%
At 1.85, Exited 1.87
With the FDA approval for the PSVT drug expected soon and a strong financial position, I believe Milestone Pharmaceuticals could see significant growt...
Read
More
Thesis
With the FDA approval for the PSVT drug expected soon and a strong financial position, I believe Milestone Pharmaceuticals could see significant growth. The potential for a billion-dollar revenue drug and non-dilutive funding solidifies my stance that this stock is poised to rise.
Go back
